Fei Su-Hai, Liu Zhen-Feng, Xie Hai-Ning, Tong Jia-Ni, Fang Zheng-Mei, Chen Yan, Yao Ying-Shui
School of Public Health, Wannan Medical College, Wuhu, China.
Wannan Medical College, Institute of Chronic Disease Prevention and Control, Wuhu, China.
Front Cardiovasc Med. 2022 Oct 26;9:994826. doi: 10.3389/fcvm.2022.994826. eCollection 2022.
In this study, the diagnostic value of microRNAs (miRNAs) for hypertension (HTN) with left ventricular hypertrophy (LVH) were evaluated by meta-analysis. A correlation study of the diagnostic value of miRNAs in HTN with LVH was conducted using a computer search of the China Knowledge Network (CNKI), Wanfang, VIP, China Biomedical Literature Database (CBM), PubMed, Web of Science, and Embase. Studies from the time of database creation to May 2022 were evaluated. The quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool in RevMan 5.3 was used to evaluate the quality of the literature, and Meta-Disc 1.4 and Stata 16.0, were used to calculate the combined sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic advantage ratio (DOR), and their 95% confidence intervals. Subject working characteristic curves were plotted and the area under the curve (AUC) was calculated using Stata 16.0. Seven publications and 8 studies were included. miRNA diagnoses of HTN with LVH had SEN = 0.84, SPE = 0.80, PLR = 4.2, NLR = 0.20, DOR = 21, and AUC = 0.89. Subgroup analysis showed that the sensitivity of plasma miRNA for the diagnosis of HTN with LVH was 0.85, which was higher than that of serum which was 0.83. The specificity of serum miRNA for the diagnosis of HTN with LVH was 0.82, which was higher than that of plasma which was 0.78, and the diagnostic accuracy of miRNA in serum DOR was 23, which was higher than that of plasma DOR which was 20. In the diagnosis of HTN with LVH, miRNA has high sensitivity and specificity and is a better biological marker.
http://www.crd.york.ac.uk/PROSPERO/, CRD42022346686.
在本研究中,通过荟萃分析评估了微小RNA(miRNA)对伴有左心室肥厚(LVH)的高血压(HTN)的诊断价值。使用计算机检索中国知网(CNKI)、万方、维普、中国生物医学文献数据库(CBM)、PubMed、Web of Science和Embase,对miRNA在伴有LVH的HTN中的诊断价值进行相关性研究。评估了从数据库创建到2022年5月的研究。使用RevMan 5.3中的诊断准确性研究质量评估-2(QUADAS-2)工具评估文献质量,并使用Meta-Disc 1.4和Stata 16.0计算合并敏感度(SEN)、特异度(SPE)、阳性似然比(PLR)、阴性似然比(NLR)、诊断优势比(DOR)及其95%置信区间。绘制受试者工作特征曲线,并使用Stata 16.0计算曲线下面积(AUC)。纳入了7篇出版物和8项研究。miRNA对伴有LVH的HTN的诊断中,SEN = 0.84,SPE = 0.80,PLR = 4.2,NLR = 0.20,DOR = 21,AUC = 0.89。亚组分析显示,血浆miRNA对伴有LVH的HTN诊断的敏感度为0.85,高于血清的0.83。血清miRNA对伴有LVH的HTN诊断的特异度为0.82,高于血浆的0.78,血清中miRNA诊断的DOR为23,高于血浆的DOR为20。在伴有LVH的HTN诊断中,miRNA具有较高的敏感度和特异度,是一种较好的生物标志物。